1. Home
  2. EEX vs PHAR Comparison

EEX vs PHAR Comparison

Compare EEX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EEX
  • PHAR
  • Stock Information
  • Founded
  • EEX 2013
  • PHAR 1988
  • Country
  • EEX United States
  • PHAR Netherlands
  • Employees
  • EEX N/A
  • PHAR N/A
  • Industry
  • EEX Advertising
  • PHAR Biotechnology: Pharmaceutical Preparations
  • Sector
  • EEX Consumer Discretionary
  • PHAR Health Care
  • Exchange
  • EEX Nasdaq
  • PHAR Nasdaq
  • Market Cap
  • EEX 1.0B
  • PHAR 1.0B
  • IPO Year
  • EEX 2017
  • PHAR N/A
  • Fundamental
  • Price
  • EEX $4.96
  • PHAR $14.60
  • Analyst Decision
  • EEX Strong Buy
  • PHAR Strong Buy
  • Analyst Count
  • EEX 2
  • PHAR 3
  • Target Price
  • EEX $7.95
  • PHAR $30.00
  • AVG Volume (30 Days)
  • EEX 34.7K
  • PHAR 11.5K
  • Earning Date
  • EEX 10-29-2025
  • PHAR 10-23-2025
  • Dividend Yield
  • EEX 1.22%
  • PHAR N/A
  • EPS Growth
  • EEX N/A
  • PHAR N/A
  • EPS
  • EEX 0.04
  • PHAR N/A
  • Revenue
  • EEX $432,600,000.00
  • PHAR $339,836,000.00
  • Revenue This Year
  • EEX $15.99
  • PHAR $16.63
  • Revenue Next Year
  • EEX $7.56
  • PHAR $6.77
  • P/E Ratio
  • EEX $134.21
  • PHAR N/A
  • Revenue Growth
  • EEX 9.96
  • PHAR 22.44
  • 52 Week Low
  • EEX $3.22
  • PHAR $7.06
  • 52 Week High
  • EEX $6.45
  • PHAR $17.08
  • Technical
  • Relative Strength Index (RSI)
  • EEX 50.11
  • PHAR 57.37
  • Support Level
  • EEX $4.80
  • PHAR $13.51
  • Resistance Level
  • EEX $5.45
  • PHAR $15.61
  • Average True Range (ATR)
  • EEX 0.22
  • PHAR 0.87
  • MACD
  • EEX -0.02
  • PHAR -0.06
  • Stochastic Oscillator
  • EEX 37.69
  • PHAR 59.37

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: